A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

NCT02514603 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm

Interventions

DRUG: Prexasertib

Sponsor

Eli Lilly and Company